Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia
Open Access
- 1 November 2001
- journal article
- case report
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 28 (9), 895-897
- https://doi.org/10.1038/sj.bmt.1703242
Abstract
Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that has recently become available for use in patients with relapsing or refractory acute myeloid leukemia. Reversible hepatotoxicity is common after administration. We describe the first report of hepatic veno-occlusive disease (HVOD) developing after Mylotarg infusion in a patient who underwent hematopoietic stem cell transplantation 8 months earlier. Certain antineoplastic agents have been implicated as a cause of HVOD, but the disease is most commonly seen within 30 days after hematopoietic stem cell transplantation. The possible association between Mylotarg infusion and HVOD is discussed. Bone Marrow Transplantation (2001) 28, 895–897.Keywords
This publication has 3 references indexed in Scilit:
- THE PATHOLOGY, DIAGNOSIS, AND TREATMENT OF HEPATIC VENO‐OCCLUSIVE DISEASE: CURRENT STATUS AND NOVEL APPROACHESBritish Journal of Haematology, 1999
- Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin ImmunoconjugateBlood, 1999
- Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantationHistopathology, 1999